



Model List of Essential Medicines



Allopurinol [General information](#)

Section

Supportive medicines

- Parenteral > General injections > IV: 500 mg (as sodium) powder for injection
- Oral > Solid: 100 mg; 300 mg

Indications

[Tumour lysis syndrome](#)



Darbepoetin alfa [General information](#)

Section

Supportive medicines

Indications

Therapeutic equivalent to [erythropoiesis-stimulating agents](#) for [Drug-induced aplastic anaemia](#)



Epoetin alfa [General information](#)

Section

Supportive medicines

Indications

Therapeutic equivalent to [erythropoiesis-stimulating agents](#) for [Drug-induced aplastic anaemia](#)



Epoetin beta [General information](#)

Section

Supportive medicines

Indications

Therapeutic equivalent to [erythropoiesis-stimulating agents](#) for [Drug-induced aplastic anaemia](#)



Erythropoiesis-stimulating agents [General information](#)

Section

Supportive medicines

- Parenteral > General injections > unspecified: 2000 IU per mL in vial (single-dose); 3000 IU per mL in vial (single-dose); 4000 IU per mL in vial (single-dose); 10000 IU per mL in vial (single-dose); 40000 IU per mL in vial (single-dose); 20000 IU per mL in vial (multiple-dose); 20000 IU per 2 mL in vial (multiple-dose)

Indications

[Drug-induced aplastic anaemia](#)



Mesna [General information](#)

Section

Supportive medicines

- Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule
- Oral > Solid: 400 mg; 600 mg
- Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 2 mL ampoule
- Oral > Solid > tablet: 400 mg; 600 mg
- Oral > Other: 600 mg
- Oral > Solid > tablet: 400 mg

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Osteosarcoma of bone and articular cartilage of other specified sites](#) [Burkitt lymphoma including Burkitt leukaemia](#) [Ewing sarcoma of bone and articular cartilage of unspecified sites](#) [Malignant neoplasms of kidney, except renal pelvis](#) [Other specified malignant neoplasms of the ovary](#) [Germ cell tumour of testis](#) [Rhabdomyosarcoma primary site](#)



Rasburicase [General information](#)

Section

Supportive medicines

- Parenteral > General injections > IV: 1.5 mg in vial powder and 1 mL solvent for solution; 7.5 mg in vial powder and 5 mL solvent for solution

Indications

[Tumour lysis syndrome](#)



Zoledronic acid [General information](#)

Section

Supportive medicines

- Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle

Indications

[Malignant neoplasm metastasis in bone or bone marrow](#)